ASCO Highlights: Insights on Hormonal Therapy for Early Breast Cancer

Debu Tripathy, CURE's editor-in-chief, is in Chicago for the annual meeting of the American Society of Clinical Oncology. He explains an analysis of two early-stage breast cancer studies in premenopausal women. The study revealed that exemestane was better than tamoxifen in patients who had ovarian blockade. After four years there was a reduction in recurrence risk, as well as a slight increase in survival. An analysis that would compare these results to tamoxifen alone is still awaited.